Japanese cedar pollinosis
Conditions
Interventions
For the immunotherapy group, cedar pollen allergy patients with positive serum cedar pollen-specific IgE, aged 5 years and over who opted for treatment with Cidacure cedar pollen sublingual tablets.
F
Sponsors
Nippon Medical School
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. for the immunotherapy group, cedar pollen allergy patients with positive serum cedar pollen-specific IgE, aged 5 years and over who opt for treatment with Cidacure cedar pollen sublingual tablets 2. for the drug treatment group, cedar pollen allergy patients with positive serum cedar pollen-specific IgE, aged 5 years and over who opted for treatment with a therapeutic agent other than sublingual immunotherapy 3. for the control group, non-allergic rhinitis patients with negative serum IgE antibodies, aged 15 years and over who are continuing in-patient treatment for symptom relief 4. those who have been informed about the study using the consent document and have given their consent.
Exclusion criteria
Exclusion criteria: 1. persons who have developed allergic symptoms as a result of diagnosis or treatment with allergen extracts or consumption of foods containing cedar pollen 2. persons who currently suffer from bronchial asthma . 3. persons with malignant tumours or systemic diseases affecting the immune system. 4. persons with wounds or inflammation in the oral cavity or after oral surgery such as tooth extraction 5. persons on non-selective beta-blockers 6. persons on tricyclic antidepressants and monoamine oxidase inhibitors 7. persons with severe cardiac or pulmonary disease and hypertension 8. persons receiving systemic steroids 9. pregnant or lactating women 10. persons with a history or illness that adversely affects immunotherapy 11. any other person who is deemed by the principal investigator or a research partner to be unsuitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Characterisation and genetic analysis of blood cells isolated from blood and analysis of proteins in serum and oral flora in saliva in the effective and ineffective immunotherapy groups. | — |
Countries
Japan
Contacts
Public ContactMinoru Gotoh
Nippon Medical School Dept. of Otorhinolaryngology
Outcome results
None listed